GHRS GH Research PLC Quick Ratio

The current financial health of GH Research PLC (GHRS) relies on remaining raised capital while inhalation products undergo verification. The market price confirmed by the chart, where the indicator stands at 27.35, accompanies the strategic push to implement patented 5-MeO-DMT for the treatment of treatment-resistant depression. Business efficiency is increasing through the integration of AI analytics and bioscreening automation, which completely eliminates monotonous manual labor for scientists.

The ratio is calculated as the sum of cash and accounts receivable divided by current liabilities, excluding illiquid inventories to assess immediate solvency. For GH Research PLC (GHRS), whose developments are in the testing phase without current sales, this metric reflects a margin of safety provided by raised capital, which the annual quick liquidity trend clearly demonstrates.